FRESCO

NCT02273375 📎

Regimen

Experimental
Fruquintinib 5 mg QD (3 weeks on/1 week off) + BSC
Control
Placebo + BSC

Population

Metastatic CRC, 3L+, refractory to standard therapy; China-only trial (N=416), 28 Chinese centers.

Key finding

3L+ mCRC (post-≥2 prior lines including oxaliplatin+irinotecan): mOS fruquintinib 9.3 vs placebo 6.57 mo (HR 0.65, 95% CI 0.51-0.83, p<0.001); mPFS 3.7 vs 1.8 mo (HR 0.26, 95% CI 0.21-0.34, p<0.001); ORR 4.7% vs 0%; DCR 62.2% vs 12.3%; fruquintinib 5mg d1-21 q28d

Source: PMID 29946728

Timeline

    Guideline citations

    • NCCN Colon (p.46)
    • NCCN Rectal (p.63)